Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 4,672 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Respiratory Therapy Clear all

Conditions: Hypertension, Pulmonary
Interventions: Selexipag, Placebo, Standard of Care (SOC): Endothelin receptor antagonist, SOC: Phosphodiesterase type 5 (PDE-5) inhibitor, SOC: Soluble guanylate cyclase stimulator; Drug
Lead sponsor: Actelion; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more

Conditions: Lung Cancer
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pneumonia, Pediatric Respiratory Diseases, Antibiotic Use, Community-acquired Pneumonia
Interventions: Supportive Care + Amoxicillin, Supportive Care + Placebo (no antibiotics); Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 12 Months to 71 Months
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non-small Cell Lung Cancer
Interventions: Docetaxel-Carboplatin; Drug
Lead sponsor: Michael Mann; Network
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Breast Cancer, Sarcoma, Bladder Cancer, Lung Cancer, Prostate Cancer, Cervical Cancers, Head and Neck Cancers, Adrenal Gland Tumors
Interventions: IDOV-Immune (oncolytic vaccinia virus); Biological
Lead sponsor: ViroMissile, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: St Louis, Missouri • Houston, Texas • San Antonio, Texas

Conditions: Obstructive Sleep Apnea Hypopnea, OSA, OSAH
Interventions: Provent Professional Sleep Apnea Therapy Device, Sham Device; Device
Lead sponsor: Ventus Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 17
States / cities: Glendale, Arizona • Phoenix, Arizona • Redwood City, California + 14 more

Conditions: Migraine
Interventions: DC Stimulator (Transcranial Direct Current Stimulator); Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pleural Empyema
Interventions: shortened antibiotic course, Standard medical treatment; Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 99 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases, Chronic Graft Versus Host Disease
Interventions: Belumosudil, Fluticasone, Azithromycin, Prednisone, Montelukast; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Stanford, California • Boston, Massachusetts • Ann Arbor, Michigan + 1 more

Conditions: Asthma
Interventions: JNJ39758979, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 14
States / cities: Scottsdale, Arizona • Cypress, California • Los Angeles, California + 11 more

Conditions: Hypertension, Substance Abuse, Asthma, Depression
Interventions: Primary care redesign; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 816 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 10
States / cities: Birmingham, Alabama • Martinez, California • San Francisco, California + 6 more

Conditions: Lung Cancer
Interventions: (99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose), 18 F FDG followed by PET/CT imaging; Drug
Lead sponsor: Cell>Point LLC; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Decatur, Illinois

Conditions: HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
Interventions: ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Trastuzumab emtansine; Drug
Lead sponsor: Enliven Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Aurora, Colorado • Orlando, Florida • Plantation, Florida + 2 more

Conditions: Lung Cancer, Pleural Effusion
Interventions: ZD6474; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2
Interventions: Anti-Sars-CoV-2 Convalescent Plasma; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: Not listed
U.S. locations: 26
States / cities: Oceanside, California • San Diego, California • Fort Carson, Colorado + 15 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution, Vibrating Mesh Nebulizer, Metered Dose Inhaler, Jet Nebulizer; Drug · Device
Lead sponsor: Polarean, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Cancer, Solid Tumor
Interventions: Fludarabine, Cyclophosphamide, IMA101 product, Recombinant human interleukin-2, IMADetect, Atezolizumab; Drug · Biological · Diagnostic Test
Lead sponsor: Immatics US, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Respiratory Distress Syndrome (ARDS)
Interventions: Inhaled Carbon Monoxide at 100ppm (4 participants), Placebo for Inhaled Carbon Monoxide at 100ppm (2 participants), Inhaled Carbon Monoxide at 200ppm (4 participants), Placebo for Inhaled Carbon Monoxide at 200ppm (2 participants); Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York • Durham, North Carolina

Conditions: Lung Cancer
Interventions: carboplatin, erlotinib hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation, radiation therapy; Drug · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 99
States / cities: Castro Valley, California • Fremont, California • Martinez, California + 72 more

Conditions: Aspergillosis, Lung Diseases, Fungal
Interventions: Itraconazole oral solution; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Covid19
Interventions: AntiCov-220, AntiCov-220 (placebo); Drug
Lead sponsor: Nguyen Thi Trieu, MD; Individual
Eligibility: 16 Years to 82 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: COPD
Interventions: myAirvo3, Pulse oximeter; Device
Lead sponsor: Temple University; Other
Eligibility: 30 Years and older
Enrollment: 642 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 25
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 20 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Zinc, Placebos for zinc and nicotinamide riboside, Nicotinamide riboside; Drug · Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Covid-19, ARDS, Human, Acute Lung Injury
Interventions: Heparin, 0.9% Sodium-chloride; Drug
Lead sponsor: Frederick Health; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Frederick, Maryland

Search by objective public record fields.

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

Surveillance For New Lung Primaries

Supportive Treatment and Antibiotics for Mild Pediatric Pneumonia

Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer

IDOV-Immune for Advanced Solid Tumors

Randomized Study of Provent Versus Sham Device to Treat Obstructive Sleep Apnea

Migraine--Investigational Treatment of Migraine With Noninvasive Brain Stimulation. (tDCS- Migraine)

Evaluating Antibiotic Course Upon Adequate Treatment of Empyema

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

A Study of the Safety and Effectiveness of JNJ-39758979 in the Treatment of Adults With Persistent Asthma

Linking Former Inmates to Primary Care

A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Malignant Pleural Effusion With ZD6474

Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)

Comparison of Bronchodilator Response From Three Different Aerosol Delivery Methods in Patients With COPD Using Hyperpolarized Xe 129 MRI Ventilation Imaging

ACTolog in Patients With Solid Cancers

Safety Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS)

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin to Placebo in the Treatment of Aspergilloma

Prevention and Treatment of Patient Before, During, and After Covid-19 Infection

myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis

Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury